Publications
Detailed Information
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Myung-Deok | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Lim, Joo Han | - |
dc.contributor.author | Yi, Hyeon Gyu | - |
dc.contributor.author | Kim, Dae-Young | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2010-03-31T05:55:35Z | - |
dc.date.available | 2010-03-31T05:55:35Z | - |
dc.date.created | 2020-12-22 | - |
dc.date.created | 2020-12-22 | - |
dc.date.created | 2020-12-22 | - |
dc.date.created | 2020-12-22 | - |
dc.date.created | 2020-12-22 | - |
dc.date.issued | 2008-09 | - |
dc.identifier.citation | Japanese Journal of Clinical Oncology, Vol.38 No.9, pp.589-595 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.other | 119532 | - |
dc.identifier.uri | https://hdl.handle.net/10371/62211 | - |
dc.description.abstract | Objective: We analysed the efficacy and toxicity of irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) chemotherapy as second-line treatment for metastatic or relapsed gastric cancer (MRGC) in a clinical practice setting. Factors to select patients who may benefit from salvage chemotherapy was also analysed. Methods: Patients with MRGC with progression on or within 6 months after discontinuing platinum-based chemotherapy received FOLFIRI as second-line therapy. The FOLFIRI regimen consisted of irinotecan (180 mg/m(2); day 1) combined with leucovorin (200 mg/m(2)), followed by 5-fluorouracil (400 mg/m(2)) as a bolus and 600 mg/m(2) as a 22-h infusion on days 1 and 2 every 2 weeks. Results: Fifty-one patients received a total of 282 courses of chemotherapy. No patients had complete remission (CR), but 9 patients achieved partial remission (PR). Stable disease (SD) was documented in 15 patients. The median progression-free survival (PFS) and overall survival (OS) were 3.2 and 9.1 months, respectively. Toxicities were tolerable and grade 3/4 neutropenia was observed in 49 cycles (17%). In multivariate analysis, patients with less organ involvement by metastasis and good performance status (PS) were independently associated with a longer PFS and OS (P < 0.05). Disease control (CR, PR or SD) after first-line chemotherapy were related to a longer PFS (P = 0.02), but had no effect on OS. Conclusions: FOLFIRI was tolerable and showed modest activity as a second-line therapy in MRGC. Less organ involvement by metastasis or good PS may be optimal selection criteria for patients with MRGC who are suitable for second-line chemotherapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | Oxford University Press | - |
dc.title | Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1093/jjco/hyn078 | - |
dc.citation.journaltitle | Japanese Journal of Clinical Oncology | - |
dc.identifier.wosid | 000259203800002 | - |
dc.identifier.scopusid | 2-s2.0-52449106480 | - |
dc.citation.endpage | 595 | - |
dc.citation.number | 9 | - |
dc.citation.startpage | 589 | - |
dc.citation.volume | 38 | - |
dc.identifier.sci | 000259203800002 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Wook | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | LOW-DOSE PACLITAXEL | - |
dc.subject.keywordPlus | INFUSIONAL 5-FLUOROURACIL | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | BIWEEKLY REGIMEN | - |
dc.subject.keywordPlus | PLUS IRINOTECAN | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | DNA-DAMAGE | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | second-line | - |
dc.subject.keywordAuthor | irinotecan | - |
dc.subject.keywordAuthor | FOLFIRI | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.